Bio-Rad LaboratoriesvsJohnson & Johnson

BIO and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

BIO

Bio-Rad Laboratories, Inc.

$358.19

Value $9.8B

-0.57%
BIO's page

Bio-Rad Laboratories (BIO) has a market value of $9.8B and Johnson & Johnson (JNJ) $672B. Over the last year, with dividends, BIO moved +14.4% and JNJ +45.4%. The P/E is 9.6 for BIO and 41.7 for JNJ. Dividend yield: BIO none, JNJ 1.89%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    BIO$9.8B

    JNJ$672B

    JNJ is 69 times BIO

  • Revenue, 12 months

    BIO$2.6B

    JNJ$99.3B

    JNJ is 38 times BIO

  • Net income, 12 months

    BIO$1.0B

    JNJ$16.1B

    JNJ is 16 times BIO

  • Operating margin

    BIO-2.4%

    JNJ–

  • ROIC

    BIO-0.6%

    JNJ12.4%

    13.0 points apart

  • P/E

    BIO9.6

    JNJ41.7

    JNJ is 4.4 times BIO

  • Dividend yield

    BIO0.0%

    JNJ1.9%

    1.9 points apart

  • 5-year return

    BIO-53.5%

    JNJ+97.0%

    150.5 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

BIO-53.5%

JNJ+97.0%

5010015020020222023202420252026
Returns by period
PeriodBIOWith dividendsJNJWith dividends
1 year since November 14, 2025+14.4%Price +14.4%+45.4%Price +42.2%
3 years since November 17, 2023+19.7%+6.2% a yearPrice +19.7%+102.6%+26.5% a yearPrice +86.1%
5 years since November 16, 2021-53.5%-14.2% a yearPrice -53.5%+97.0%+14.5% a yearPrice +71.3%
10 years since November 17, 2016+106.1%+7.5% a yearPrice +106.1%+213.7%+12.1% a yearPrice +139.1%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

BIOBio-Rad LaboratoriesJNJJohnson & Johnson

Valuation

BIOJNJ
Valuation
Price$358.19$278.70
Market value$9.8B$672B
Enterprise value (EV)$8.9B$699B
P/E9.641.7
P/E, 5-year median–21.9
P/B1.38.2
EV/EBIT–39.4
Free cash flow yield3.4%3.1%

Results and growth

BIOJNJ
Results and growth
Revenue, 12 months$2.6B$99.3B
Net income, 12 months$1.0B$16.1B
Free cash flow, 12 months$329M$20.6B
Earnings per share, 12 months$37.71$6.59
Revenue growth, year on year0.7%6.1%
Revenue growth a year, past+0.3%over 5 years+2.7%over 5 years
EPS growth a year, past-26.1%over 5 years+14.9%over 5 years

Margins and returns on capital

BIOJNJ
Margins and returns on capital
Gross margin51.3%67.6%
Operating margin-2.4%–
Net margin39.5%16.2%
ROIC-0.6%12.4%
ROE14.3%19.7%

Balance sheet

BIOJNJ
Balance sheet
Cash$1.7B$17.2B
Total debt$971M$44.7B
Net debt / EBITDA-8.21.1
Interest cover-1.3×18.0×

Dividends and buybacks

BIOJNJ
Dividends and buybacks
Dividend yield–1.9%
Dividend per share, 12 months–$5.28
Dividend growth a year, past–+5.3%over 5 years
Buyback yield3.0%0.9%
Shareholder yield3.0%2.8%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: BIO or JNJ

Didn't find what you were looking for?

Ask us
Which is bigger, Bio-Rad Laboratories or Johnson & Johnson?

By market value, Johnson & Johnson ($672B) is about 68.8 times Bio-Rad Laboratories ($9.8B), at today's prices.

How did BIO and JNJ stock do over the last 10 years?

Since November 17, 2016, BIO's price moved +106.1% and JNJ's +139.1%. With dividends: BIO +106.1% (+7.5% a year), JNJ +213.7% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, BIO or JNJ?

The dividend yield at today's price is none for Bio-Rad Laboratories and 1.89% for Johnson & Johnson. Over the last twelve months they paid – and $5.28 per share.

What is the P/E of BIO and JNJ?

At today's price, the P/E is 9.6 for BIO and 41.7 for JNJ. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Bio-Rad Laboratories or Johnson & Johnson?

Over the last twelve months, the net margin was 39.5% for Bio-Rad Laboratories and 16.2% for Johnson & Johnson, and the operating margin -2.4% and –. Revenue was $2.6B and $99.3B.

Which is the better investment, Bio-Rad Laboratories or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.